Copaxone Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy
Conditions:   Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting Interventions:   Drug: Tecfidera (BG12);   Drug: Gilenya;   Drug: Tysabri®;   Drug: Avonex/Betaseron/Copaxone/Rebif;   Procedure: Hematopoietic stem cell transplantation (HSCT) Sponsor:   Sheffield Teaching Hospitals NHS Foundation Trust Recruiting - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 21, 2016 Category: Research Source Type: clinical trials